Nitric oxide synthase tetrahydrobiopterin binding site (NOS BH4 site)

Nitric oxide synthase (NOS) enzymes require (6R)-5,6,7,8-tetrahydrobiopterin (BH4) as an essential cofactor to catalyze the conversion of L-arginine to L-citrulline and nitric oxide (NO) (UniProt P29474, P29475, P35228). The BH4 cofactor site is located at the dimer interface of the oxygenase domain, where it stabilizes the active dimeric form of the enzyme and facilitates electron transfer to the heme center (PubMed: 16709945). When BH4 availability is low or when it is oxidized to dihydrobiopterin (BH2), the enzyme becomes uncoupled, shifting its activity from NO production to the generation of superoxide radicals (PubMed: 24603283). This uncoupling is a hallmark of endothelial dysfunction and plays a critical role in the progression of cardiovascular diseases, including hypertension and atherosclerosis (StatPearls: Nitric Oxide). Therapeutic strategies targeting this site include the administration of synthetic BH4 (sapropterin) to recouple the enzyme and restore NO bioavailability (PubChem CID 135398508). Additionally, pterin-based analogs like VAS203 are being explored as selective inhibitors of the inducible NOS (iNOS) isoform to treat inflammatory and neurotraumatic conditions by competing for this binding site (ClinicalTrials.gov: NCT01174121).

Other names

Tetrahydrobiopterin cofactor siteBH4 binding pocketNOS-BH4 interfacePterin binding site of nitric oxide synthase

Cofactor supplementation to restore enzyme coupling and nitric oxide production; competitive inhibition of the pterin site to selectively block inducible nitric oxide synthase activity.